| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-19 |
| Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects (NCT03629873) | The First Affiliated Hospital with Nanjing Medical University | 2018-02-01 |
| The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies (NCT04184414) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-01-09 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878) | Oncternal Therapeutics, Inc | 2018-01-03 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (NCT03267433) | ECOG-ACRIN Cancer Research Group | 2017-11-27 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL (NCT03019666) | Masonic Cancer Center, University of Minnesota | 2017-10-18 |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT03019640) | M.D. Anderson Cancer Center | 2017-10-10 |
| Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma (NCT03311126) | University of Wisconsin, Madison | 2017-09-29 |
| The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma (NCT03295240) | Memorial Sloan Kettering Cancer Center | 2017-09-20 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) (NCT03153202) | Joshua Brody | 2017-07-14 |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas (NCT03188965) | Bayer | 2017-07-06 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) (NCT03112174) | Pharmacyclics LLC. | 2017-06-19 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers (NCT03037645) | Sunesis Pharmaceuticals | 2017-04-28 |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients (NCT03028103) | Epizyme, Inc. | 2017-03-27 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (NCT02483000) | Fred Hutchinson Cancer Center | 2017-02-01 |
| The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma (NCT03016988) | Tingbo Liu | 2017-01-01 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (NCT02896582) | The Lymphoma Academic Research Organisation | 2016-11-29 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma (NCT02927964) | Robert Lowsky | 2016-11-07 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers (NCT02991638) | The University of Hong Kong | 2016-11-01 |
| A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents (NCT02745769) | Eli Lilly and Company | 2016-10-21 |
| Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma (NCT02840539) | Seoul National University Hospital | 2016-10-11 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02819583) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02851589) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-07-01 |
| ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma (NCT02858258) | Prof. Dr. M. Dreyling (co-chairman) | 2016-07-01 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (NCT02793583) | TG Therapeutics, Inc. | 2016-05-25 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922) | University of Washington | 2016-05-19 |
| Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL (NCT02682641) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2016-05-18 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma (NCT02756247) | Memorial Sloan Kettering Cancer Center | 2016-05-09 |
| A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (NCT02735876) | Acerta Pharma BV | 2016-05-01 |
| Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma (NCT02728531) | Washington University School of Medicine | 2016-04-18 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044) | Juno Therapeutics, a Subsidiary of Celgene | 2016-01-06 |
| EDOCH Alternating With DHAP for New Diagnosed Younger MCL (NCT02858804) | Institute of Hematology & Blood Diseases Hospital, China | 2016-01-01 |
| Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (NCT02633137) | Memorial Sloan Kettering Cancer Center | 2015-12-14 |
| Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 (NCT02507336) | University of Miami | 2015-11-24 |
| A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (NCT02558816) | Nantes University Hospital | 2015-10-14 |
| Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma (NCT02356458) | Swiss Cancer Institute | 2015-08-31 |
| ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (NCT02471391) | Peter MacCallum Cancer Centre, Australia | 2015-07-22 |
| Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (NCT02446236) | Hackensack Meridian Health | 2015-06-18 |
| Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT02427620) | M.D. Anderson Cancer Center | 2015-06-03 |
| Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT (NCT02267915) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2015-03-01 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL (NCT02142530) | Massachusetts General Hospital | 2014-10-01 |
| Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (NCT02267590) | Royal Marsden NHS Foundation Trust | 2014-10-01 |
| Safety Study of SGN-CD70A in Cancer Patients (NCT02216890) | Seagen Inc. | 2014-08-01 |
| CART-19 Immunotherapy in Mantle Cell Lymphoma (NCT02081937) | Chinese PLA General Hospital | 2014-03-01 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL (NCT01865110) | The Lymphoma Academic Research Organisation | 2013-11-01 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686) | Janssen Research & Development, LLC | 2013-09-09 |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT01880567) | M.D. Anderson Cancer Center | 2013-07-15 |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01796470) | Gilead Sciences | 2013-06-20 |
| Study of LY2835219 for Mantle Cell Lymphoma (NCT01739309) | Eli Lilly and Company | 2013-03-20 |
| Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01799889) | Gilead Sciences | 2013-03-14 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (NCT01728207) | Gilead Sciences | 2013-03-01 |
| Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma (NCT01685606) | Brown University | 2013-03-01 |
| Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy (NCT01646021) | Janssen Research & Development, LLC | 2012-12-10 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies (NCT01744912) | TG Therapeutics, Inc. | 2012-11-21 |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (NCT01500538) | Peter MacCallum Cancer Centre, Australia | 2012-10-01 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma (NCT01652144) | NCIC Clinical Trials Group | 2012-09-14 |
| Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma (NCT01661881) | Christine Ryan | 2012-08-16 |
| Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma (NCT01415752) | Eastern Cooperative Oncology Group | 2012-08-09 |
| A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy (NCT01599949) | Janssen Research & Development, LLC | 2012-08-01 |
| Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL (NCT01737177) | Fondazione Italiana Linfomi - ETS | 2012-07-31 |
| Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma (NCT01578343) | Samsung Medical Center | 2012-06-01 |
| Double Cord Versus Haploidentical (BMT CTN 1101) (NCT01597778) | Medical College of Wisconsin | 2012-06-01 |
| Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) (NCT01439750) | Milton S. Hershey Medical Center | 2012-05-01 |
| Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy (NCT03054883) | Czech Lymphoma Study Group | 2012-04-01 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01410513) | Sanofi | 2011-12-01 |
| Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (NCT01484093) | Memorial Sloan Kettering Cancer Center | 2011-11-29 |
| A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (NCT01460134) | Celldex Therapeutics | 2011-10-01 |
| Study of Mantle Cell Lymphoma Treatment by RiBVD (NCT01457144) | French Innovative Leukemia Organisation | 2011-10-01 |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine (NCT01397825) | Millennium Pharmaceuticals, Inc. | 2011-08-09 |
| Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma (NCT01472562) | Weill Medical College of Cornell University | 2011-07-29 |
| Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies (NCT01399840) | Pfizer | 2011-06-30 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas (NCT01314014) | University of Rochester | 2011-05-01 |
| Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) (NCT01504776) | Anand Jillella | 2011-04-01 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL (NCT01562977) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-04-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) (NCT01236391) | Pharmacyclics LLC. | 2011-02-01 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01251575) | Fred Hutchinson Cancer Center | 2010-12-01 |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies (NCT01263899) | S*BIO | 2010-12-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01239875) | Mayo Clinic | 2010-11-01 |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (NCT00992446) | Fred Hutchinson Cancer Center | 2010-09-02 |
| Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma (NCT01111188) | Weill Medical College of Cornell University | 2010-08-23 |